中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
10期
1418-1419
,共2页
史为涛%王勤英%赵雪%赵龙凤
史為濤%王勤英%趙雪%趙龍鳳
사위도%왕근영%조설%조룡봉
慢性乙型肝炎%阿德福韦酯%调节性T细胞%疗效
慢性乙型肝炎%阿德福韋酯%調節性T細胞%療效
만성을형간염%아덕복위지%조절성T세포%료효
Chronic hepatitis B%Adefovir dipivoxil%Regulation T cells%Efficacy
目的 探讨慢性乙型肝炎(CHB)患者接受阿德福韦酯抗病毒治疗前外周血CD4+、CD+25调节性T细胞(Treg细胞)水平与抗病毒远期临床疗效的关系.方法 选取具有抗病毒治疗适应证、核苷类似物初治的CHB患者为病例组(92例),另选取性别、年龄相匹配的10例健康者为对照组.采用流式细胞技术检测入选对象外周血Treg细胞水平.病例组给予阿德福韦酯10 mg/d抗病毒治疗,定期检测乙型肝炎病毒标志物、HBV DNA及肝功能等.结果 治疗48周时,完全应答、部分应答和无应答者分别为11、69、12例.治疗前病例组外周血Treg细胞水明显高于对照组[(8.2±5.2)％比(3.0±0.7)％,P＜0.05].无应答组外周血Treg细胞水明显高于部分应答组、完全应答组和对照组[(11.6±1.6)％比(5.6±1.3)％、(3.6±0.8)％、(3.0±0.7)％,P＜0.01]；部分应答组外周血Treg细胞水明显高于完全应答组和对照组(均P＜0.01)；完全应答组和对照组差异无统计学意义(P＞0.05).结论 CHB患者阿德福韦酯抗病毒治疗前外周血Treg细胞水平对阿德福韦酯抗病毒的远期疗效可能有一定的预测价值.
目的 探討慢性乙型肝炎(CHB)患者接受阿德福韋酯抗病毒治療前外週血CD4+、CD+25調節性T細胞(Treg細胞)水平與抗病毒遠期臨床療效的關繫.方法 選取具有抗病毒治療適應證、覈苷類似物初治的CHB患者為病例組(92例),另選取性彆、年齡相匹配的10例健康者為對照組.採用流式細胞技術檢測入選對象外週血Treg細胞水平.病例組給予阿德福韋酯10 mg/d抗病毒治療,定期檢測乙型肝炎病毒標誌物、HBV DNA及肝功能等.結果 治療48週時,完全應答、部分應答和無應答者分彆為11、69、12例.治療前病例組外週血Treg細胞水明顯高于對照組[(8.2±5.2)％比(3.0±0.7)％,P＜0.05].無應答組外週血Treg細胞水明顯高于部分應答組、完全應答組和對照組[(11.6±1.6)％比(5.6±1.3)％、(3.6±0.8)％、(3.0±0.7)％,P＜0.01]；部分應答組外週血Treg細胞水明顯高于完全應答組和對照組(均P＜0.01)；完全應答組和對照組差異無統計學意義(P＞0.05).結論 CHB患者阿德福韋酯抗病毒治療前外週血Treg細胞水平對阿德福韋酯抗病毒的遠期療效可能有一定的預測價值.
목적 탐토만성을형간염(CHB)환자접수아덕복위지항병독치료전외주혈CD4+、CD+25조절성T세포(Treg세포)수평여항병독원기림상료효적관계.방법 선취구유항병독치료괄응증、핵감유사물초치적CHB환자위병례조(92례),령선취성별、년령상필배적10례건강자위대조조.채용류식세포기술검측입선대상외주혈Treg세포수평.병례조급여아덕복위지10 mg/d항병독치료,정기검측을형간염병독표지물、HBV DNA급간공능등.결과 치료48주시,완전응답、부분응답화무응답자분별위11、69、12례.치료전병례조외주혈Treg세포수명현고우대조조[(8.2±5.2)％비(3.0±0.7)％,P＜0.05].무응답조외주혈Treg세포수명현고우부분응답조、완전응답조화대조조[(11.6±1.6)％비(5.6±1.3)％、(3.6±0.8)％、(3.0±0.7)％,P＜0.01]；부분응답조외주혈Treg세포수명현고우완전응답조화대조조(균P＜0.01)；완전응답조화대조조차이무통계학의의(P＞0.05).결론 CHB환자아덕복위지항병독치료전외주혈Treg세포수평대아덕복위지항병독적원기료효가능유일정적예측개치.
Objective To investigate the relation between levels of regulation T cells (Treg cells) of peripheral blood in chronic hepatitis B (CHB) patients before receiving adefovir dipivoxil (ADV) antiviral therapy and the long-term clinical antiviral efficacy.Methods CHB patients with antiviral therapeutic indications and initial treatment of nucleoside analogues were selected as the case group ; healthy subjects served as the control group.The levels of Treg cells of peripheral blood in the case group before receiving ADV antiviral therapy and the control group were detected by flow cytometry.The case group was given ADV 10 mg/d antiviral treatment and examined regularly on HBV markers,HBV DNA and liver function etc.Results All 92 cases were divided into complete response,response and nonresponse on the basis of its efficacy.The levels of peripheral Treg cells in the 92 cases before receiving ADV antiviral therapy was significantly higher than those in the control group [(8.23 ± 5.2) ％ vs (3.0 ±0.7) ％,P ＜ 0.05].The levels of peripheral Treg cells in the no response group was significantly higher than those in the partial response group,the complete response group and the control group [(11.6 ± 1.6) ％ vs (5.6 ±1.3) ％,(3.6 ± 0.8) ％,(3.0 ± 0.7) ％] (P ＜ 0.01).Those in partial response group was significantly higher than those in healthy control group(P ＜ 0.01).But the levels of Treg cells in the complete response group and the control group were not significantly different (P ＞ 0.05).Conclusion Levels of Treg cells of peripheral blood in CHB patients before receiving ADV antiviral therapy have some predictive value for the long-term efficacy of ADV antiviral treatment.
